Victor L J L Thijssen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5337157/publications.pdf

Version: 2024-02-01

94	5,062	76326	91884
papers	citations	40 h-index	69 g-index

96	96	96	7723
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden. Cancer Immunology, Immunotherapy, 2022, 71, 2029-2040.	4.2	13
2	Examination of the Role of Galectins and Galectin Inhibitors in Endothelial Cell Biology. Methods in Molecular Biology, 2022, 2442, 655-662.	0.9	0
3	Method to Study the Role of Galectins in Angiogenesis In Vivo Using the Chick Chorioallantoic Membrane Assay. Methods in Molecular Biology, 2022, 2442, 621-633.	0.9	1
4	Metallated phthalocyanines and their hydrophilic derivatives for multi-targeted oncological photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 2022, 234, 112500.	3.8	8
5	Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. Pharmaceuticals, 2022, 15, 796.	3.8	8
6	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. PLoS ONE, 2021, 16, e0244736.	2.5	12
7	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. Molecular Oncology, 2021, 15, 901-914.	4.6	7
8	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16
9	Galectins in Endothelial Cell Biology and Angiogenesis: The Basics. Biomolecules, 2021, 11, 1386.	4.0	17
10	Chemokines modulate glycan binding and the immunoregulatory activity of galectins. Communications Biology, 2021, 4, 1415.	4.4	5
11	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
12	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
13	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
14	Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro. , 2021, 16, e0244736.		0
15	Combining Radiation Therapy With Interferons: Back to the Future. International Journal of Radiation Oncology Biology Physics, 2020, 108, 56-69.	0.8	6
16	Development of transient radioresistance during fractionated irradiation in vitro. Radiotherapy and Oncology, 2020, 148, 107-114.	0.6	12
17	Targeting Tumor Vascular CD99 Inhibits Tumor Growth. Frontiers in Immunology, 2019, 10, 651.	4.8	17
18	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. Cancers, 2019, 11, 261.	3.7	11

#	Article	IF	Citations
19	Abstract 3738: A STING independent type-1 interferon response induced by fractionated radiotherapy coincides with altered tumor growth and clonogenicity. , 2019, , .		0
20	Different angioregulatory activity of monovalent galectin-9 isoforms. Angiogenesis, 2018, 21, 545-555.	7.2	56
21	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain, 2018, 141, 3377-3388.	7.6	32
22	Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. Frontiers in Immunology, 2018, 9, 1598.	4.8	31
23	Targeting PDGFâ€mediated recruitment of pericytes blocks vascular mimicry and tumor growth. Journal of Pathology, 2018, 246, 447-458.	4.5	67
24	Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. Frontiers in Immunology, 2018, 9, 3107.	4.8	76
25	Galectin-9. , 2018, , 1991-1996.		0
26	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis, 2017, 20, 217-232.	7.2	26
27	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0157830.	2.5	69
28	A key role for galectinâ€1 in sprouting angiogenesis revealed by novel rationally designed antibodies. International Journal of Cancer, 2016, 139, 824-835.	5.1	21
29	Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resistance Updates, 2016, 25, 26-37.	14.4	88
30	Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget, 2016, 7, 76613-76627.	1.8	27
31	Galectin-9. , 2016, , 1-6.		0
32	Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Medicine, 2015, 4, 1003-1015.	2.8	29
33	Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Molecular Cancer, 2015, 14, 71.	19.2	39
34	Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 235-247.	7.4	188
35	A common sugarâ€nucleotideâ€mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6Fâ€GalNAc (Ac ₃). FASEB Journal, 2015, 29, 2993-3002.	0.5	31
36	The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. Pharmacological Reviews, 2015, 67, 441-461.	16.0	190

#	Article	IF	Citations
37	Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis, 2015, 18, 385-395.	7.2	32
38	Examination of the Role of Galectins and Galectin Inhibitors in Endothelial Cell Biology. Methods in Molecular Biology, 2015, 1207, 285-291.	0.9	5
39	Examination of the Role of Galectins During In Vivo Angiogenesis Using the Chick Chorioallantoic Membrane Assay. Methods in Molecular Biology, 2015, 1207, 305-315.	0.9	10
40	Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer. PLoS ONE, 2015, 10, e0129119.	2.5	52
41	Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Î"5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e107988.	2.5	23
42	Introduction to special issue: Glycans in vascular biology. Glycobiology, 2014, 24, 1235-1236.	2.5	4
43	Involvement of galectin-1 in reproduction: past, present and future. Human Reproduction Update, 2014, 20, 175-193.	10.8	67
44	Introduction to special issue: Galectins go with the flow. Glycobiology, 2014, 24, 885-885.	2.5	3
45	Expression, Regulation and Function of Human Metallothioneins in Endothelial Cells. Journal of Vascular Research, 2014, 51, 231-238.	1.4	38
46	Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 284-292.	3.8	48
47	PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, 2014, 20, 741-747.	30.7	86
48	Galectin-1 and -9 in angiogenesis: A sweet couple. Glycobiology, 2014, 24, 915-920.	2.5	55
49	Galectins in tumor angiogenesis. Annals of Translational Medicine, 2014, 2, 90.	1.7	33
50	Interfering with UDP-GlcNAc Metabolism and Heparan Sulfate Expression Using a Sugar Analogue Reduces Angiogenesis. ACS Chemical Biology, 2013, 8, 2331-2338.	3.4	32
51	Vascular galectins: Regulators of tumor progression and targets for cancer therapy. Cytokine and Growth Factor Reviews, 2013, 24, 547-558.	7.2	65
52	CXCR4+ Dendritic cells promote angiogenesis during embryo implantation in mice. Angiogenesis, 2013, 16, 417-427.	7.2	36
53	Galectin-9 in tumor biology: A jack of multiple trades. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 177-185.	7.4	87
54	Tetraspanin CD63 Promotes Vascular Endothelial Growth Factor Receptor 2-Î²1 Integrin Complex Formation, Thereby Regulating Activation and Downstream Signaling in Endothelial Cells in Vitro and in Vivo. Journal of Biological Chemistry, 2013, 288, 19060-19071.	3.4	52

#	Article	IF	Citations
55	Profiling Lgals9 Splice Variant Expression at the Fetal-Maternal Interface: Implications in Normal and Pathological Human Pregnancy1. Biology of Reproduction, 2013, 88, 22.	2.7	31
56	Interfering with Gal-1â€“mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11451-11456.	7.1	93
57	Functional characterization of a STAT3-dependent dendritic cell-derived CD14⁺cell population arising upon IL-10-driven maturation. OncoImmunology, 2013, 2, e23837.	4.6	31
58	Angiostatic Cancer Therapy by Targeting Galectins in the Tumor Vasculature. ACS Symposium Series, 2012, , 233-247.	0.5	3
59	Epigenetic Regulation of Galectin-3 Expression by Î²1 Integrins Promotes Cell Adhesion and Migration. Journal of Biological Chemistry, 2012, 287, 44684-44693.	3.4	46
60	Combining angiogenesis inhibition and radiotherapy: A double-edged sword. Drug Resistance Updates, 2012, 15, 173-182.	14.4	60
61	Uterine NK Cells Are Critical in Shaping DC Immunogenic Functions Compatible with Pregnancy Progression. PLoS ONE, 2012, 7, e46755.	2.5	47
62	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano, 2011, 5, 4422-4433.	14.6	183
63	Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathology and Applied Neurobiology, 2011, 37, 654-671.	3.2	68
64	Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. British Journal of Cancer, 2011, 104, 1185-1192.	6.4	65
65	The Anti-angiogenic Peptide Anginex Greatly Enhances Galectin-1 Binding Affinity for Glycoproteins. Journal of Biological Chemistry, 2011, 286, 13801-13804.	3.4	45
66	Blocking of Frizzled Signaling With a Homologous Peptide Fragment of Wnt3a/Wnt5a Reduces Infarct Expansion and Prevents the Development of Heart Failure After Myocardial Infarction. Circulation, 2011, 124, 1626-1635.	1.6	122
67	Abstract 3490: Identification and characterization of novel galectin-9 splice variants in endothelial cells. , 2011, , .		0
68	MicroRNAs in the tumor endothelium: Novel controls on the angioregulatory switchboard. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 87-96.	7.4	45
69	Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor. Circulation Research, 2010, 106, 155-165.	4.5	54
70	Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity. Cancer Research, 2010, 70, 6216-6224.	0.9	210
71	Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Molecular Cancer, 2010, 9, 152.	19.2	112
72	Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology, 2009, 19, 68-75.	2.5	29

#	Article	IF	Citations
73	One less concern. Nature, 2009, 457, 628-628.	27.8	0
74	A low frequency of lymph node metastasis in clearâ€cell renal cell carcinoma is related to low lymphangiogenic activity. BJU International, 2009, 103, 1626-1631.	2.5	19
75	The Galectin Profile of the Endothelium. American Journal of Pathology, 2008, 172, 545-553.	3.8	175
76	Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango. Current Pharmaceutical Design, 2007, 13, 3576-3583.	1.9	15
77	Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood, 2007, 110, 2819-2827.	1.4	118
78	Targeted gene-delivery strategies for angiostatic cancer treatment. Trends in Molecular Medicine, 2007, 13, 200-209.	6.7	22
79	Anginex-Conjugated Liposomes for Targeting of Angiogenic Endothelial Cells. Bioconjugate Chemistry, 2007, 18, 785-790.	3.6	41
80	High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRTâ€“PCR mRNA expression profile. British Journal of Cancer, 2007, 96, 1888-1895.	6.4	70
81	Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochemical and Biophysical Research Communications, 2006, 349, 1073-1078.	2.1	28
82	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15975-15980.	7.1	424
83	Antiâ€angiogenesis therapy can overcome endothelial cell anergy and promote leukocyteâ€endothelium interactions and infiltration in tumors. FASEB Journal, 2006, 20, 621-630.	0.5	237
84	Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Molecular Human Reproduction, 2006, 12, 367-375.	2.8	60
85	Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochemical and Biophysical Research Communications, 2005, 333, 1261-1268.	2.1	25
86	Antiangiogenesis Therapy for Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1089-1095.	3.6	215
87	Temporal and Spatial Variations in Structural Protein Expression During the Progression From Stunned to Hibernating Myocardium. Circulation, 2004, 110, 3313-3321.	1.6	29
88	17Î²-Estradiol Antagonizes Cardiomyocyte Hypertrophy by Autocrine/Paracrine Stimulation of a Guanylyl Cyclase A Receptor-Cyclic Guanosine Monophosphate-Dependent Protein Kinase Pathway. Circulation, 2004, 109, 269-276.	1.6	99
89	Troponin I Isoform Expression in Human and Experimental Atrial Fibrillation. Circulation, 2004, 110, 770-775.	1.6	22
90	Angiogenic Profile of Breast Carcinoma Determines Leukocyte Infiltration. Clinical Cancer Research, 2004, 10, 7171-7178.	7.0	47

#	Article	IF	Citations
91	Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research, 2004, 299, 286-293.	2.6	76
92	Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovascular Research, 2002, 54, 427-437.	3.8	39
93	Structural remodelling during chronic atrial fibrillation: act of programmed cell survival. Cardiovascular Research, 2001, 52, 14-24.	3.8	103
94	Structural Changes of Atrial Myocardium During Chronic Atrial Fibrillation. Cardiovascular Pathology, 2000, 9, 17-28.	1.6	122